Citius Oncology, Inc. Financing Cash Flow
Citius Oncology, Inc. (CTOR) reported Financing Cash Flow of $33.54 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-14
- Citius Oncology, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $18.64M.
- Citius Oncology, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$231.20K.
- Citius Oncology, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $15.13M.
- Citius Oncology, Inc. net cash provided by (used in) financing activities for the quarter ending 2024-06-30 was $264.39K.
- Citius Oncology, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $15.17M, a 211.19% increase from fiscal 2024.
- Citius Oncology, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $4.87M.
- Citius Oncology, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $1.66M, a 97.54% decline from fiscal 2022.
- Citius Oncology, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $67.66M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $18.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-14 | $18.41M derived: sum of 2 quarters · filed 2026-08-14 | $33.54M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | -$231.20K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-15 | $14.89M 10-Q · filed 2026-05-15 | ||
| 2025-12-31 | $15.13M 10-Q · filed 2026-02-13 | |||
| 2025-09-30 | $15.17M 10-K · filed 2025-12-23 | |||
| 2024-09-30 | $4.87M 10-K · filed 2025-12-23 | |||
| 2024-06-30 | $264.39K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$24.28M 10-Q · filed 2024-08-09 | -$23.40M derived: sum of 3 quarters · filed 2024-08-09 | -$22.97M derived: sum of 4 quarters · filed 2024-08-09 |
| 2024-03-31 | -$24.55M 10-Q · filed 2024-05-20 | -$23.66M derived: sum of 2 quarters · filed 2024-05-20 | -$23.23M derived: sum of 3 quarters · filed 2024-05-20 | |
| 2023-12-31 | $885.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | $1.31M derived: sum of 2 quarters · filed 2024-04-16 | $1.66M 10-K · filed 2024-04-16 | |
| 2023-09-30 | $429.90K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-20 | $779.88K 10-Q · filed 2023-11-20 | ||
| 2023-06-30 | $349.98K 10-Q · filed 2024-08-09 | |||
| 2022-12-31 | $67.66M 10-K · filed 2024-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |